Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme

New England Journal of Medicine

Volumn 372, Issue 21, 2015, Pages 1987-1995

  Krug, Norbert ^a   Hohlfeld, Jens M ^a   Kirsten, Anne Marie ^c   Kornmann, Oliver ^d   Beeh, Kai M ^e   Kappeler, Dominik ^f   Korn, Stephanie ^g   Ignatenko, Stanislav ^h   Timmer, Wolfgang ^f   Rogon, Cordelia ⁱ   Zeitvogel, Jana ^b   Zhang, Nan ^l,m   Bille, Joachim ^j   Homburg, Ursula ^j   Turowska, Agnieszka ^j   Bachert, Claus ^l,m   Werfel, Thomas ^b   Buhl, Roland ^g   Renz, Jonas ^j   Garn, Holger ^k   Renz, Harald ^k   more..

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Pulmonary Research Institute   (Germany)

^d IKF Clinical Research Centre Respiratory Medicine   (Germany)

^e Institut fur Atemwegsforschung INSAF   (Germany)

^f Inamed GmbH   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ FGK Clinical Research   (Germany)

^j Sterna Biologicals   (Germany)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DEOXYRIBOZYME; INTERLEUKIN 5; METHACHOLINE; NITRIC OXIDE; PLACEBO; SB 010; TRANSCRIPTION FACTOR GATA 3; TRYPTASE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER; MESSENGER RNA; RIBONUCLEASE; SB010 DNAZYME;

ADULT; ALLERGIC ASTHMA; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHUS OBSTRUCTION; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HEADACHE; HERPES SIMPLEX; HUMAN; INCREASED UPPER AIRWAY SECRETION; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAUSEA; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; RHINOPHARYNGITIS; SCIATICA; SPUTUM EOSINOPHILIA; TREATMENT RESPONSE; UPPER AIRWAY COUGH SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; BLOOD; CLINICAL TRIAL; GENETICS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHENOTYPE; TH2 CELL; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA; BIOLOGICAL MARKERS; DNA, CATALYTIC; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; GATA3 TRANSCRIPTION FACTOR; HUMANS; INTERLEUKIN-5; MALE; MIDDLE AGED; PHENOTYPE; RIBONUCLEASES; RNA, MESSENGER; TH2 CELLS; YOUNG ADULT;

EID: 84929774279     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1411776     Document Type: Article

References (45)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2014. August 12, 2014 (http://www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf).
2. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev 2011;242:220-32.
3. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
4. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012;18:673-83.
5. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-25.
6. Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest 1999;104:985-93.
7. Bergqvist A, Andersson CK, Hoffmann HJ, et al. Marked epithelial cell pathology and leukocyte paucity in persistently symptomatic severe asthma. Am J Respir Crit Care Med 2013;188:1475-7.
8. Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol 2012;33:238-46.
9. Santiago FS, Khachigian LM. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J Mol Med (Berl) 2001;79:695-706.
10. Cho EA, Moloney FJ, Cai H, et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet 2013;381:1835-43.
11. Sel S, Wegmann M, Dicke T, et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 2008;121(4):910.e5-916.e5.
12. Turowska A, Librizzi D, Baumgartl N, et al. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol Appl Pharmacol 2013;272:365-72.
13. Dicke T, Pali-Schöll I, Kaufmann A, Bauer S, Renz H, Garn H. Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes. Nucleic Acid Ther 2012;22:117-26.
14. Fuhst R, Runge F, Buschmann J, et al. Toxicity profile of the GATA-3-specific DNAzyme hgd40 after inhalation exposure. Pulm Pharmacol Ther 2013;26:281-9.
15. Homburg U, Renz H, Timmer W, et al. Safety and tolerability of a novel inhaled GATA 3 mRNA targeting DNAzyme in Th2-driven asthma. J Allergy Clin Immunol 2015 April 1 (Epub ahead of print).
16. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78.
17. Brand P, Beckmann H, Maas Enriquez M, et al. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003;22:263-7.
18. Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135:264-7.
19. Diamant Z, Gauvreau GM, Cockcroft DW, et al. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol 2013;132(5):1045.e6-1055.e6.
20. Gauvreau GM, Watson RM, Rerecich TJ, Baswick E, Inman MD, O'Byrne PM. Repeatability of allergen-induced airway inflammation. J Allergy Clin Immunol 1999;104:66-71.
21. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
22. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999: this official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29.
23. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
24. Janssen O, Schaumann F, Holz O, et al. Low-dose endotoxin inhalation in healthy volunteers - a challenge model for early clinical drug development. BMC Pulm Med 2013;13:19.
25. O'Byrne PM. Allergen-induced airway inflammation and its therapeutic intervention. Allergy Asthma Immunol Res 2009;1:3-9.
26. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31.
27. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66.
28. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-96.
29. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
30. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
31. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
32. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
33. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012;130:829-42.
34. Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102-10.
35. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199-208.
36. Vijverberg SJ, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L. Clinical utility of asthma biomarkers: from bench to bedside. Biologics 2013;7:199-210.
37. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650-8.
38. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013;19:977-9.
39. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
40. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987;79:734-40.
41. Winandy S, Brown M. No DL1 Notch ligand? GATA be a mast cell. Nat Immunol 2007;8:796-8.
42. Mjösberg J, Bernink J, Golebski K, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012;37:649-59.
43. Sadat MA, Kumatori A, Suzuki S, Yamaguchi Y, Tsuji Y, Nakamura M. GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells. FEBS Lett 1998;436:390-4.
44. Gauvreau GM, Boulet LP, Postma DS, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005;116:285-91.
45. Kent SE, Boyce M, Diamant Z, et al. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 2013;43:177-86.